Long Ideas - Keryx Biopharmaceuticals’ (KERX) CEO, Ron Bentsur, spent much of the company’s 4Q/YE12 earnings conference call reviewing patents, pending patents, and potential exclusivity designations for Zerenex, … Continue Reading
Read nowLong Ideas - The spin doctors have done a great job pressuring Keryx BioPharmaceuticals (KERX) recently, pulling out all the stops to drive the stock down. Massive share … Continue Reading
Read nowLong Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) has been a booming success for PropThink, with the stock doubling since PropThink first got behind the Zerenex data in mid-October. And, our … Continue Reading
Read nowLong Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) miscalculated the timing for when its CRO (contract research organization) would deliver Phase III results for Zerenex, the company’s phosphate-binder candidate for … Continue Reading
Read nowLong Ideas - Keryx Biopharmaceuticals (NASDAQ:KERX) announced Monday morning that its Japanese development partner JT Tori Pharmaceutical Co. submitted a new drug application (NDA) for Zerenex, the company’s … Continue Reading
Read nowMost Popular - Keryx Biopharmaceuticals (KERX) issued a press release on Thursday morning related to the Medicare bundle for oral-only phosphate binders, which would positively impact the company’s lead candidate … Continue Reading
Read nowLong Ideas - In the next several weeks, Keryx Biopharmaceuticals (KERX) will release results from 4 key Phase III trials for its primary drug candidate, Zerenex. The drug … Continue Reading
Read now